Follow-up: Tirzepatide and nausea: is the profile genuinely different or just differently reported? posts 91–120

SURMOUNT-1 reported weight reduction of a magnitude that was the largest for a pharmacological intervention at that time of publication. It also reported a clear dose response across three doses. The categorical thresholds (people reaching 10%, 15%, 20% loss) got the most attention but read less informatively than the mean weight change.

Second-hand, so weight it accordingly.

I had written a reply contradicting post #102 and deleted it. Here is what survived.

Titration schedules for tirzepatide have more dose steps than semaglutide partly because the compound is more potent and partly because the clinical programme used a finer gradation. That does not mean you cannot escalate on a coarser schedule if that suits you — the published schedule is not a lower bound.

Posting it because the silence on this was starting to look like agreement.

Adding the measurement that post #104 says would settle it.

A note on how Tirzepatide and nausea gets discussed rather than on Tirzepatide and nausea itself: the confident posts get the replies and the careful ones get ignored, and the careful ones have been right more often.

Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial reported gastrointestinal effects broadly comparable in character. Individual variation is the largest factor.

Comparisons between the tirzepatide and semaglutide programmes across trials rather than within one are weak. Different populations, different durations, different baseline characteristics; the only fair comparison is a head-to-head one.

If anyone can point at the primary source I would be grateful.

Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.

I have seen it go both ways, which is why I hedge.

Coming back to post #109, because the follow-up matters more than the original answer.

On Tirzepatide and nausea: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.

Post #109 is right about the mechanism and I think understates the practical bit.

I would put moderate confidence on the mainstream reading of Tirzepatide and nausea and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.

Following, with nothing to contribute beyond having asked the same thing elsewhere.

I had written a reply contradicting post #112 and deleted it. Here is what survived.

The GIP component: GIP receptor agonism is thought to amplify the GLP-1 effect on satiety and energy expenditure, but how much of tirzepatide's effect is that and how much is simply achieving higher receptor occupancy remains genuinely open. The mechanistic literature is active.

The strength of my opinion here exceeds the strength of my evidence.

Storage and stability: published data on licensed tirzepatide formulations exists and is worth reading directly rather than through summarised claims. Reconstituted preparations in different diluents have not been studied and extrapolation from the licensed formulation is the best you can do.

If that is already documented somewhere, ignore me and link it.

SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose. That is the central and legitimate criticism of the head-to-head evidence and it is worth remembering when people quote the trial.

This has been discussed before and I could not find the thread, so, again.

The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against placebo and cannot say anything about the shape of the relationship.

Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means steady state is reached slightly faster and the post-dose swing is slightly larger. Most people do not report noticing the difference in practical terms.

Where I would look next, rather than where I would stop.

Fine by me. I had wanted a stronger conclusion and there is not one available.